NCT01733810View on ClinicalTrials.gov

The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 1, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2019

Conditions
EsophagitisReflux EsophagitisGastroesophageal Reflux Disease
Interventions
OTHER

Cessation of Acid Suppressing Medications

Acid-suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations performed while participant is not on acid-suppressing medications.

Trial Locations (1)

75216

Dallas VA Medical Center, Dallas

Sponsors
All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Dallas VA Medical Center

FED

NCT01733810 - The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis | Biotech Hunter | Biotech Hunter